VICO-SS: KOL Webinar and Meeting with Management Keep Us Bullish on IPF Market Opportunity and Buloxibutid's Potential Role In It

Research evidence excerpt

VICO-SS: KOL Webinar and Meeting with Management Keep Us Bullish on IPF Market Opportunity and Buloxibutid's Potential Role In It

FLASH NOTE

June 8, 2026

Vamil Divan, M.D. vamil.divan@guggenheimpartners.com VICO-SS: KOL Webinar and Meeting with

212 823 6543 Management Keep Us Bullish on IPF Market

Daniel Krizay, Ph.D.

daniel.krizay@guggenheimpartners.com Opportunity and Buloxibutid's Potential Role In It

212 823 6561

Arseniy Shabashvili Key Message: Vicore's investor webinar today featuring pulmonologist Dr. Phil

arseniy.shabashvili@guggenheimpartners.com Molyneaux (Imperial College London), alongside our recent discussion with CEO Ahmed 212 699 1971

Mousa and CMO Dr. Bernt van den Blink, reinforced our positive view on buloxibutid as

Edouard Mullarky, Ph.D. a differentiated and combinable drug candidate for the treatment of idiopathic pulmonary

edouard.mullarky@guggenheimpartners.com fibrosis (IPF). Despite the recent FDA approval of BI's Jascayd and UTHR's pending

212 518 9579 Tyvaso sNDA, Dr. Molyneaux and other physicians we have spoken to continue to

believe there is opportunity for significant improvement with next-generation therapies,

particularly those with a more tolerable clinical profile. We believe the upcoming 4Q 2026

VICO-SS pre-specifieda potential meaningfulinterim futilityde-riskingreadoutcatalystfrom theirheadingongoingintoPhasethe key2b ASPIREmid-2027trialtoplinerepresentsdata

Vicore Pharma Holding AB release. The company also highlighted the new clinical and pre-clinical data presented at

Sector: Biotechnology ATS last month, which while incremental, provides additional data supporting the drug's

therapeutic potential in IPF and other indications. We remain encouraged by both Vicore's